Title:
DIAGNOSTIC AGENT AND MEDICINE COMPRISING ADAMTS13 AS MAIN INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2017/119498
Kind Code:
A1
Abstract:
Provided is a novel use of ADAMTS13 in the medical field. Use of ADAMTS13 as a biomarker for monitoring the onset of hepatopathy, hepatic ischemia/reperfusion injury or hepatic function after liver transplantation; a method for examining hepatopathy, a method for examining hepatic ischemia/reperfusion injury or a method for examining hepatic function after liver transplantation, each method comprising measuring or monitoring ADAMTS13 activity in a sample obtained from a mammal; and a therapeutic agent for a disease selected from the group consisting of hepatopathy, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, said agent comprising ADAMTS13 or a modification thereof.
Inventors:
HATA KOICHIRO (JP)
UEMOTO SHINJI (JP)
HIRAO HIROFUMI (JP)
KUBOTA TOYONARI (JP)
UEMOTO SHINJI (JP)
HIRAO HIROFUMI (JP)
KUBOTA TOYONARI (JP)
Application Number:
PCT/JP2017/000316
Publication Date:
July 13, 2017
Filing Date:
January 06, 2017
Export Citation:
Assignee:
UNIV KYOTO (JP)
THE CHEMO-SERO-THERAPEUTIC RES INST (JP)
THE CHEMO-SERO-THERAPEUTIC RES INST (JP)
International Classes:
G01N33/68; A61K38/46; A61P1/16; C12M1/34; C12N9/64; C12Q1/37; G01N33/50
Foreign References:
| JP2010280571A | 2010-12-16 | |||
| JP2012103211A | 2012-05-31 | |||
| JP2013505270A | 2013-02-14 |
Other References:
YOSHIHIRO FUJIMURA ET AL.: "Control of arterial thrombosis: basic and clinical research on the VWF-GPIb axis-dependent thrombotic disorders, modulated by ADAMTS13", SAISHIN IGAKU = MODERN MEDICINE, vol. 64, no. 2, February 2009 (2009-02-01), pages 132 (290) - 163 (321), XP009512156, ISSN: 0370-8241
KANDUTSCH, S. ET AL.: "Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases", EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, vol. 34, no. 11, 12 February 2008 (2008-02-12), pages 1231 - 1236, XP025582817
KHAN, A.Z. ET AL.: "Patterns of chemotherapy- induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases", JOURNAL OF HEPATOBILIARY PANCREATIC SURGERY, vol. 16, no. 2, 18 December 2008 (2008-12-18), pages 137 - 144, XP019719392
RUBBIA-BRANDT, L. ET AL.: "Severe hepatic sinusoidal obstruction associated with oxaliplatin-basedchemotherapy in patients with metastatic colorectal cance r", ANNALS OF ONCOLOGY, vol. 15, no. 3, 1 March 2004 (2004-03-01), pages 460 - 466, XP055399054
HUGENHOLTZ, G.C.G. ET AL.: "An Unbalance Between von Willebrand Factor and ADAMTS13 in Acute Liver Failure: Implications for Hemostasis and Clinical Outcome", HEPATOLOGY, vol. 58, August 2013 (2013-08-01), pages 752 - 761, XP055399056
KO, S. ET AL.: "Plasma ADAMTS13 Activity May Predict Early Adverse Events in Living Donor Liver Transplantation: Observations in 3 Cases", LIVER TRANSPLANTATION, vol. 12, no. 5, May 2006 (2006-05-01), pages 859 - 869, XP055399061
KUME, Y. ET AL.: "Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats", FEBS LETTERS, vol. 581, 20 March 2007 (2007-03-20), pages 1631 - 1634, XP022024555
UEMURA, M. ET AL.: "Decreased Activity of Plasma ADAMTS13 May Contribute to the Development of Liver Disturbance and Multiorgan Failure in Patients with Alcoholic Hepatitis", ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESERCH, vol. 29, December 2005 (2005-12-01), pages 264S - 271S, XP055399063
See also references of EP 3401685A4
KANDUTSCH, S. ET AL.: "Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases", EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, vol. 34, no. 11, 12 February 2008 (2008-02-12), pages 1231 - 1236, XP025582817
KHAN, A.Z. ET AL.: "Patterns of chemotherapy- induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases", JOURNAL OF HEPATOBILIARY PANCREATIC SURGERY, vol. 16, no. 2, 18 December 2008 (2008-12-18), pages 137 - 144, XP019719392
RUBBIA-BRANDT, L. ET AL.: "Severe hepatic sinusoidal obstruction associated with oxaliplatin-basedchemotherapy in patients with metastatic colorectal cance r", ANNALS OF ONCOLOGY, vol. 15, no. 3, 1 March 2004 (2004-03-01), pages 460 - 466, XP055399054
HUGENHOLTZ, G.C.G. ET AL.: "An Unbalance Between von Willebrand Factor and ADAMTS13 in Acute Liver Failure: Implications for Hemostasis and Clinical Outcome", HEPATOLOGY, vol. 58, August 2013 (2013-08-01), pages 752 - 761, XP055399056
KO, S. ET AL.: "Plasma ADAMTS13 Activity May Predict Early Adverse Events in Living Donor Liver Transplantation: Observations in 3 Cases", LIVER TRANSPLANTATION, vol. 12, no. 5, May 2006 (2006-05-01), pages 859 - 869, XP055399061
KUME, Y. ET AL.: "Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats", FEBS LETTERS, vol. 581, 20 March 2007 (2007-03-20), pages 1631 - 1634, XP022024555
UEMURA, M. ET AL.: "Decreased Activity of Plasma ADAMTS13 May Contribute to the Development of Liver Disturbance and Multiorgan Failure in Patients with Alcoholic Hepatitis", ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESERCH, vol. 29, December 2005 (2005-12-01), pages 264S - 271S, XP055399063
See also references of EP 3401685A4
Attorney, Agent or Firm:
SAMEJIMA, Mutsumi et al. (JP)
Download PDF:
Previous Patent: CONVERTER
Next Patent: A combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor
Next Patent: A combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor